Week of Mar 10 – Mar 14, 2026 — Comprehensive analysis of 10 active merger arbitrage opportunities with spread calculations, risk assessments, and return projections.
This week's merger arbitrage landscape presents a favorable environment for spread investors. With 10 active deals representing $196B in aggregate transaction value, opportunity breadth remains strong. The average gross spread sits at 4.79% with an average annualized return of 16.3%.
4 deals carry low regulatory risk with clear paths to closing. 3 deals remain elevated-risk due to ongoing antitrust reviews or complex deal structures — these offer the highest spreads for those with conviction. The top opportunity this week is AbbVie → Aliada Therapeutics at 34.2% annualized.
Phase 2 data readout could affect deal; antitrust low-risk
CFIUS national security review ongoing
State regulatory approvals pending; shareholder approved
Get complete analysis for all 10 active M&A opportunities with spread data, risk ratings, and return projections.
Subscribe — $29/moGross spread = (Offer Price − Current Price) / Current Price × 100. Annualized return accounts for days to expected close date, assuming reinvestment at the same rate.
Risk ratings consider regulatory complexity (antitrust, CFIUS, sector-specific), financing conditions, shareholder approval status, and historical deal break rates for similar transaction types.
Reports are published weekly on Fridays. Prices reflect the most recent market close. Deal status, risk ratings, and analyst notes are updated as material developments occur.
Get the complete weekly M&A Spread Analysis Report with all deal data, risk ratings, return calculations, and analyst notes. Cancel anytime.
Secure checkout via Stripe · Cancel anytime